Table 1.
Patient Characteristics
| All patients (n = 208) | Primary prevention (n = 115) | Secondary prevention (n = 93) | p–value | |
|---|---|---|---|---|
| Age, years | 60 ± 12 | 60 ± 11 | 59 ± 13 | 0.532 |
| Gender, male, n(%) | 174 (84) | 98 (85) | 76 (82) | 0.498 |
| BMI, kg/m2 | 28.6 ± 5.1 | 29.2 ± 5.3 | 27.9 ± 4.8 | 0.062 |
| Hypertension, n(%) | 144 (69) | 80 (70) | 64 (69) | 0.907 |
| Diabetes, n(%) | 46 (22) | 32 (28) | 14 (15) | 0.027 |
| CHA2DS2–VASc Score | 2.7 ± 1.4 | 2.8 ± 1.2 | 2.4 ± 1.5 | 0.006 |
| NYHA class | 1.9 ± 0.9 | 2.1 ± 0.9 | 1.6 ± 1.0 | 0.001 |
| Known CAD, n(%) | 83 (40) | 52 (45) | 31 (33) | 0.082 |
| Severity of CAD | 0.178 | |||
| Single–vessel, n(%) | 31 (37) | 18 (35) | 13 (42) | |
| Multi–vessel, n(%) | 52 (63) | 34 (65) | 18 (58) | |
| Electrical instability | 0.009 | |||
| ≤ 2 adequate ATP/shock(s), n(%) | 23 (11) | 16 (14) | 7 (8) | |
| Electrical storm, n(%) | 107 (51) | 53 (46) | 54 (58) | |
| Below detection, n(%) | 11 (5) | 3 (3) | 8 (9) | |
| Inadequate ATP/shock(s), n(%) | 15 (7) | 6 (5) | 9 (10) | |
| Prior VT ablation, n(%) | 50 (24) | 16 (14) | 34 (37) | < 0.001 |
| Antiarrhythmic drugs | ||||
| Betablockers, n(%) | 189 (91) | 104 (90) | 85 (91) | 0.811 |
| Class I, n(%) | 14 (7) | 5 (4) | 9 (10) | 0.127 |
| Class III, n(%) | 60 (29) | 31 (27) | 29 (31) | 0.504 |
| Device characteristics | 0.070 | |||
| S–ICD, n(%) | 6 (3) | 5 (4) | 1 (1) | |
| Single chamber ICD, n(%) | 101 (49) | 55 (48) | 46 (49) | |
| Dual chamber ICD, n(%) | 65 (31) | 30 (26) | 35 (38) | |
| CRT–D, n(%) | 36 (17) | 25 (22) | 11 (12) | |
| MR-conditional devices, n(%) | 94 (45) | 48 (42) | 46 (49) | 0.266 |
| Time since ICD implantation, months | 58.9 ± 50.0 | 56.4 ± 42.4 | 61.9 ± 58.2 | 0.436 |
| Range, months | 1.4–240.4 | 1.6–225.0 | 1.4–240.4 | |
Values are mean ± SD or n (%); p-values are given for the comparison of primary versus secondary prevention. BMI body mass index; CAD coronary artery disease; ATP antitachycardia pacing; VT ventricular tachycardia; ICD implanted cardioverter defibrillator; S–ICD subcutaneous implantable cardioverter defibrillator; CRT–D cardiac resynchronization therapy defibrillator, MR magnetic resonance